Granzymes and Perforin at the Onset of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00883701|
Recruitment Status : Completed
First Posted : April 20, 2009
Last Update Posted : April 29, 2010
COPD exacerbations are characterized by an excessive accumulation and activation of inflammatory cells in the airways. It is not known whether this phenomenon represents a risk for for lung damage via the release in the extracellular environment of potent cytolitic cellular granular contents such as granzymes and perforin.
The investigators assess the intracellular expression of granzymes and perforin in neutrophils and large granular lymphocytes (LGL) at the onset of exacerbations compared to stable disease.
The investigators hypothesize that a greater release of intracellular perforin and granzymes from neutrophils and LGL into the extracellular environment occur at exacerbations compared to stable condition and that these changes are more pronounced in COPD patients than in subjects without COPD who undergo respiratory infection.
|Condition or disease|
|Chronic Obstructive Pulmonary Disease|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Observational Model:||Case Control|
|Official Title:||Granzymes and Perforin at the Onset of COPD Exacerbations|
|Study Start Date :||December 2002|
|Actual Primary Completion Date :||August 2008|
|Actual Study Completion Date :||September 2009|
COPD patients who undergo exacerbation
Non COPD patients (controls)
Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
- Expression of granzymes and perforin in neutrophiles and LGL sputum cells [ Time Frame: 6 months ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00883701
|University Hospital Larisa|
|Larisa, Thessaly, Greece|
|Study Director:||Demos Makris, MD||University of Thessaly|